SEC Form 4 · accession 0001209191-15-070343

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Sep 9, 2015

Accepted (ET)

Sep 11, 2015 · 4:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001347178

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 9, 2015	M	42,747	$4.73	A	800,894	D
Common Stock^F1,F2	Sep 9, 2015	S	29,577	$12.5092	D	771,317	D
Common Stock	Sep 10, 2015	M	147,626	$4.73	A	918,943	D
Common Stock^F1,F3	Sep 10, 2015	S	102,162	$12.7298	D	816,781	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4	$4.73	Sep 9, 2015	M	42,747	D	—	Dec 19, 2015	Common Stock	42,747	147,626	D
Employee Stock Option (Right to Buy)^F4	$4.73	Sep 10, 2015	M	147,626	D	—	Dec 19, 2015	Common Stock	147,626	0	D

F1Represents shares of common stock sold to cover the payment of the option exercise price and to satisfy tax obligations relating to exercise of the option, which is scheduled to expire on December 19, 2015.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.87, inclusive.
F4Became exercisable with respect to 25% of the shares on December 29, 2006 and with respect to an additional 2.08333% of the aggregate shares each month thereafter.